Literature DB >> 9150393

Two functional assays employed to detect an unusual mutation in the oligomerisation domain of p53 in a Li-Fraumeni like family.

M E Lomax1, D M Barnes, R Gilchrist, S M Picksley, J M Varley, R S Camplejohn.   

Abstract

Previous investigations of a Li - Fraumeni like family (Barnes et al., 1992) demonstrated that both the proband and her mother had elevated p53 protein levels in both tumour tissue and normal tissue at sites distant from the tumour, although no mutation was found in the p53 gene. In the present study two recently described functional assays for p53, an apoptotic assay and the functional assay for the separation of alleles in yeast (FASAY), have been employed to study the functional activity of p53 from this patient. The results of the apoptotic assay demonstrated that this patient had a p53 functional defect and the FASAY result suggested that this defect was in fact a germline mutation of the p53 gene. A point mutation of codon 337, which results in an amino acid substitution of a cysteine for an arginine, was demonstrated initially in cDNA and was confirmed by sequencing of genomic DNA. This is an unusual mutation as it is in the oligomerisation domain of p53, in contrast to the majority of p53 mutations which are in the core DNA binding domain. This mutation results in a protein which still retains partial transactivational activity in the FASAY. The mutation of codon 337 is only the second reported case of a germline missense mutation occurring in the oligomerisation domain of p53.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9150393     DOI: 10.1038/sj.onc.1201133

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  20 in total

Review 1.  Genotype phenotype correlation in Li-Fraumeni syndrome kindreds and its implications for management.

Authors:  R N Moule; S G Jhavar; R A Eeles
Journal:  Fam Cancer       Date:  2006       Impact factor: 2.375

2.  Improving the detection of p53 mutations in breast cancer by use of the FASAY, a functional assay.

Authors:  P M Duddy; A M Hanby; D M Barnes; R S Camplejohn
Journal:  J Mol Diagn       Date:  2000-08       Impact factor: 5.568

3.  An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma.

Authors:  R C Ribeiro; F Sandrini; B Figueiredo; G P Zambetti; E Michalkiewicz; A R Lafferty; L DeLacerda; M Rabin; C Cadwell; G Sampaio; I Cat; C A Stratakis; R Sandrini
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-31       Impact factor: 11.205

4.  The need for dynamic methods for measuring cell cycle perturbations: a study in radiation-treated lymphoblastoid cell lines of varying p53 status.

Authors:  R Gilchrist; M E Lomax; R S Camplejohn
Journal:  Cell Prolif       Date:  1999-02       Impact factor: 6.831

Review 5.  p53 functional assays: detecting p53 mutations in both the germline and in sporadic tumours.

Authors:  R S Camplejohn; J Rutherford
Journal:  Cell Prolif       Date:  2001-02       Impact factor: 6.831

6.  The role of p53 as a surrogate marker for chemotherapeutical responsiveness in ovarian cancer.

Authors:  Dirk O Bauerschlag; Christian Schem; Marion T Weigel; Constantin Von Kaisenberg; Alexander Strauss; Thomas Bauknecht; Nicolai Maass; Ivo Meinhold-Heerlein
Journal:  J Cancer Res Clin Oncol       Date:  2010-01       Impact factor: 4.553

7.  Regional analysis of p53 mutations in rheumatoid arthritis synovium.

Authors:  Yuji Yamanishi; David L Boyle; Sanna Rosengren; Douglas R Green; Nathan J Zvaifler; Gary S Firestein
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-15       Impact factor: 11.205

Review 8.  p53: the attractive tumor suppressor in the cancer research field.

Authors:  Toshinori Ozaki; Akira Nakagawara
Journal:  J Biomed Biotechnol       Date:  2010-12-06

9.  Investigations on a clinically and functionally unusual and novel germline p53 mutation.

Authors:  J Rutherford; C E Chu; P M Duddy; R S Charlton; P Chumas; G R Taylor; X Lu; D M Barnes; R S Camplejohn
Journal:  Br J Cancer       Date:  2002-05-20       Impact factor: 7.640

10.  Hypoxia facilitates tumour cell detachment by reducing expression of surface adhesion molecules and adhesion to extracellular matrices without loss of cell viability.

Authors:  N M Hasan; G E Adams; M C Joiner; J F Marshall; I R Hart
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.